Encorafenib

Encorafenib, also known as LGX-818, is an orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells.
Supplier Alfa Cytology
Product # BC0540
Pricing 10.0 mg, 25.0 mg, 50.0 mg, 100.0 mg, 200.0 mg, inquire
Feedback